US92532F1003
© BusinessWire
22.12.2025
VRTX
LISTED
NASDAQ
Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT.
A live webcast of management’s remarks will be available through the Vertex website, ww...
Themefolio
Profiler
Peergroup
© BusinessWire
06.12.2025
VRTX
LISTED
NASDAQ
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clin...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2025
VRTX
LISTED
NASDAQ
Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in Citi’s 2025 Global Healthcare Conference. Charlie Wagner, Chief Operating and Financial Officer, and David Altshuler, Chief Scientific Officer, will participate in a fireside chat on Wednesday, December 3, 2025, at 9:00 a.m. ET.
A live webcast of manag...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
08.11.2025
VRTX
LISTED
NASDAQ
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic an...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
03.11.2025
VRTX
LISTED
NASDAQ
Vertex Reports Third Quarter 2025 Financial Results
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance.
“Vertex delivered strong results across the board in the third quarter, extending our leadership in CF, continuing to build global momentum for CASGEVY, an...
Themefolio
Profiler
Peergroup
© BusinessWire
27.10.2025
VRTX
LISTED
NASDAQ
Vertex to Participate in the UBS Global Healthcare Conference on November 11
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the UBS Global Healthcare Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, November 11, 2025, at 10:15 a.m. ET.
A live webcast of management’s remarks will be available through the Ve...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2025
VRTX
LISTED
NASDAQ
Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company’s most recently approved medicine, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), at the North American Cystic Fibrosis Conference (NACFC) held fro...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
VRTX
LISTED
NASDAQ
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-i...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
VRTX
LISTED
NASDAQ
Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2025 financial results on Monday, November 3, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Ve...
Themefolio
Profiler
Peergroup
© BusinessWire
25.09.2025
VRTX
LISTED
NASDAQ
Vertex Announces Key Advancements Across Kidney Portfolio
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important advancements across its programs in immunoglobulin A Nephropathy (IgAN), APOL1-mediated kidney disease (AMKD) and autosomal dominant polycystic kidney disease (ADPKD). These updates represent significant progress toward reaching the Company’s goal of bringing forw...
Themefolio
Profiler
Peergroup
© BusinessWire
23.09.2025
VRTX
LISTED
NASDAQ
Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with basketball world champion Jayson Tatum to raise awareness of JOURNAVX® (suzetrigine), a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain in adults and the first new class of pain medicine approved in more than 2...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2025
VRTX
LISTED
NASDAQ
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy
News Preview
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel).
“Today is a turning point for eligible...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
11.09.2025
VRTX
LISTED
NASDAQ
Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year’s Lasker~DeBakey Clinical Medical Research Award for his role “in the development of a novel, life-saving treatment for cystic fibrosis (CF) — namely, a triple-drug combination therapy, TRIK...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2025
VRTX
LISTED
NASDAQ
Vertex to Participate in Upcoming September Investor Conferences
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences.
Susie Lisa, Senior Vice President, Investor Relations, and Manisha Pai, Executive Director, Investor Relations, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, Septem...
Themefolio
Profiler
Peergroup
© PR Newswire
22.07.2025
VRTX
LISTED
NASDAQ
Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis
News Preview
- In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1 and superior in reducing sweat chloride compared to TRIKAFTA -
- Approximately 3,800 people in Canada are now eligible for ALYFTREK, with up to 60 people potentially eligible for a medicine that treats the underlying cause of their disease for the first time -
TORONTO, July 2...
Themefolio
Profiler
Peergroup
© BusinessWire
15.07.2025
VRTX
LISTED
NASDAQ
Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement with NHS England for Vertex’s cystic fibrosis (CF) medicine ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor). This agreement comes as the National Institute for Health and Care Excellence (NICE) has issued a positive final draft r...
Themefolio
Profiler
Peergroup
© BusinessWire
14.07.2025
VRTX
LISTED
NASDAQ
Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading health care improvement company. The honor recognizes JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with m...
Themefolio
Profiler
Peergroup
© BusinessWire
08.07.2025
VRTX
LISTED
NASDAQ
Vertex to Announce Second Quarter 2025 Financial Results on August 4th
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vert...
Themefolio
Profiler
Peergroup
© PR Newswire
03.07.2025
VRTX
LISTED
NASDAQ
Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY
News Preview
- Data from longer-term follow-up of patients in ongoing clinical trials further demonstrate durability of the clinical benefits of CASGEVY® -
- Multiple reimbursement agreements secured, expanding access to CASGEVY to more patients around the world -
TORONTO, July 3, 2025 /CNW/ - Vertex Pharmaceuticals (Nasdaq: VRTX) recently announced positive...
Themefolio
Profiler
Peergroup
© BusinessWire
01.07.2025
VRTX
LISTED
NASDAQ
Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis
News Preview
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene....
Themefolio
Profiler
Peergroup
© BusinessWire
23.06.2025
VRTX
LISTED
NASDAQ
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (...
Themefolio
Profiler
Peergroup
© BusinessWire
21.06.2025
VRTX
LISTED
NASDAQ
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impair...
Themefolio
Profiler
Peergroup
© BusinessWire
06.06.2025
VRTX
LISTED
NASDAQ
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
VRTX
LISTED
NASDAQ
Vertex to Participate in Upcoming Investor Conferences
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences.
Susie Lisa, Senior Vice President, Investor Relations, and Manisha Pai, Executive Director, Investor Relations, will participate in the Evercore Biotechnology Summit on Wednesday, May 21, 2025.
Dr. Reshma Kewalram...
Themefolio
Profiler
Peergroup
© BusinessWire
05.05.2025
VRTX
LISTED
NASDAQ
Vertex Reports First Quarter 2025 Financial Results
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2025, and raised the low end of its total revenue guidance range by $100 million, from $11.75 billion to $12 billion to a new range of $11.85 billion to $12 billion.
“Vertex delivered a strong start to 2025 with n...
Themefolio
Profiler
Peergroup
© BusinessWire
11.04.2025
VRTX
LISTED
NASDAQ
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner International Award “for pioneering research into the cellular and molecular mechanisms underlying the genetic disease cystic fibrosis, leading to the development of transformative dr...
Themefolio
Profiler
Peergroup
© BusinessWire
07.04.2025
VRTX
LISTED
NASDAQ
Vertex to Announce First Quarter 2025 Financial Results on May 5th
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex P...
Themefolio
Profiler
Peergroup
© BusinessWire
07.04.2025
VRTX
LISTED
NASDAQ
European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis
News Preview
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of people with cystic fibrosis (CF). With this approval, the indication has been expanded to include all pa...
Themefolio
Profiler
Peergroup
© BusinessWire
28.03.2025
VRTX
LISTED
NASDAQ
Vertex Announces Program Updates for Type 1 Diabetes Portfolio
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D) portfolio.
VX-264 Update
Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B. In Part B of the study, participants received t...
Themefolio
Profiler
Peergroup
© BusinessWire
07.03.2025
VRTX
LISTED
NASDAQ
Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
News Preview
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator treatment for peo...
Themefolio
Profiler
Peergroup
© BusinessWire
28.02.2025
VRTX
LISTED
NASDAQ
Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
News Preview
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor for the treatment of people with cystic fibrosis (CF) aged 2 years and...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
VRTX
LISTED
NASDAQ
Vertex to Participate in Upcoming March Investor Conferences
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences.
Stuart Arbuckle, Executive Vice President and Chief Operating Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer will participate in a fireside chat at...
Themefolio
Profiler
Peergroup
© BusinessWire
10.02.2025
VRTX
LISTED
NASDAQ
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided its full year 2025 financial guidance.
“2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another important year with the landmark JOURNAVX app...
Themefolio
Profiler
Peergroup
© BusinessWire
31.01.2025
VRTX
LISTED
NASDAQ
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
News Preview
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel).
The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guid...
Themefolio
Profiler
Peergroup
© BusinessWire
31.01.2025
VRTX
LISTED
NASDAQ
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an effective, well-tolerated medicine without eviden...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2025
VRTX
LISTED
NASDAQ
Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and re...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2025
VRTX
LISTED
NASDAQ
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 a.m. ET/7:30 a.m. PT.
“2024 marked another year of excellent progress fo...
Themefolio
Profiler
Peergroup
© BusinessWire
10.01.2025
VRTX
LISTED
NASDAQ
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a rec...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2025
VRTX
LISTED
NASDAQ
Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
News Preview
-- Collaboration to leverage Orna's differentiated lipid nanoparticle (LNP) delivery solutions for patients with SCD and TDT --
-- Orna to receive an upfront payment and is eligible to receive potential pre-clinical, clinical, and commercialization milestone payments and royalties --
WATERTOWN, Mass., Jan. 7, 2025 /PRNewswire/ -- Orna Therapeutic...
Themefolio
Profiler
Peergroup
© BusinessWire
23.12.2024
VRTX
LISTED
NASDAQ
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT.
A live webcast of management's remarks will be available through the Vertex website, ww...
Themefolio
Profiler
Peergroup
© BusinessWire
20.12.2024
VRTX
LISTED
NASDAQ
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 ye...
Themefolio
Profiler
Peergroup
© BusinessWire
20.12.2024
VRTX
LISTED
NASDAQ
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane...
Themefolio
Profiler
Peergroup
© BusinessWire
19.12.2024
VRTX
LISTED
NASDAQ
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy (LSR). The study met its primary endpoint with statistically significant and clinically meaningful reduction in pa...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2024
VRTX
LISTED
NASDAQ
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first and only approved CRISPR/Cas9 gene-edited therapy.
The results, presented at...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
VRTX
LISTED
NASDAQ
Vertex Reports Third Quarter 2024 Financial Results
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2024, and raised its full-year product revenue guidance to $10.8 billion to $10.9 billion.
“The third quarter marked another period of strong progress, with continued revenue growth and outstanding execution a...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2024
VRTX
LISTED
NASDAQ
Vertex to Participate in Upcoming November Investor Conferences
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.
Dr. Reshma Kewalramani, Chief Executive Officer and President, will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 9:00 a.m. ET.
Stuart A...
Themefolio
Profiler
Peergroup
© BusinessWire
25.10.2024
VRTX
LISTED
NASDAQ
Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on multiple kidney diseases in its pipeline including IgA nephropathy (IgAN), primary membranous nephropathy (pMN), and APOL1-mediated kidney disease (AMKD). These updates demonstrate the transformative potential of Vertex’s investigational therapies in multiple serious kidn...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2024
VRTX
LISTED
NASDAQ
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain, at the annual meeting of the American Society of Anesthesiologists (ASA), taking place...
Themefolio
Profiler
Peergroup
© BusinessWire
10.10.2024
VRTX
LISTED
NASDAQ
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Ver...
Themefolio
Profiler
Peergroup
© PR Newswire
26.09.2024
VRTX
LISTED
NASDAQ
Vertex Announces Health Canada Acceptance of New Drug Submission for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic Fibrosis
News Preview
TORONTO, Sept. 26, 2024 /CNW/ - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has accepted for review its New Drug Submission (NDS) for vanzacaftor/tezacaftor/deutivacaftor, a once-daily triple combination therapy for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508d...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2024
VRTX
LISTED
NASDAQ
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first accepted medical presentations of the Phase 3 data on the investigational once daily vanzacaftor/tezacaftor/deutivacaftor (“vanza triple”) — the potential next-in-class triple combination medicine — will take place at the North American Cystic Fibrosis Conference (NACFC)....
Themefolio
Profiler
Peergroup
© PR Newswire
25.09.2024
VRTX
LISTED
NASDAQ
Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
News Preview
– First regulatory authorization of a CRISPR-based gene-editing therapy in Canada –
TORONTO, Sept. 25, 2024 /CNW/ - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced Health Canada has granted Marketing Authorization for PrCASGEVY® (exagamglogene autotemcel), an autologous genome edited hematopoietic stem cell-based therapy, for...
Themefolio
Profiler
Peergroup
© BusinessWire
22.08.2024
VRTX
LISTED
NASDAQ
Vertex to Participate in Upcoming September Investor Conferences
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.
Dr. Reshma Kewalramani, Chief Executive Officer and President, and Charles Wagner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global He...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
